-
公开(公告)号：US20140377270A1
公开(公告)日：2014-12-25
申请号：US14207489
申请日：2014-03-12
申请人： Gregory Moore , Matthew Bernett , Rumana Rashid , John Desjarlais
发明人： Gregory Moore , Matthew Bernett , Rumana Rashid , John Desjarlais
IPC分类号： C07K16/28
CPC分类号： C07K16/2803 , C07K16/2809 , C07K16/468 , C07K2317/31 , C07K2317/55 , C07K2317/565 , C07K2317/62 , C07K2317/622
摘要： The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
摘要翻译： 本发明涉及用于各种双特异性形式的优化的抗CD3可变序列，包括利用scFv组分的那些。 本发明还涉及编码多肽的核酸，包含其的载体和包含载体的宿主细胞。 另一方面，本发明提供包含所述多肽的药物组合物和多肽的医学用途。
-
公开(公告)号：US20210171596A1
公开(公告)日：2021-06-10
申请号：US16798247
申请日：2020-02-21
申请人： Gregory Moore , Rajat Varma , Yoon Kyung Kim , Rumana Rashid , Eric W. Chang , Alex Nisthal , Juan Diaz , Matthew Bernett , Michael Hedvat
发明人： Gregory Moore , Rajat Varma , Yoon Kyung Kim , Rumana Rashid , Eric W. Chang , Alex Nisthal , Juan Diaz , Matthew Bernett , Michael Hedvat
IPC分类号： C07K14/54
摘要： The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.
-
公开(公告)号：US20070054359A1
公开(公告)日：2007-03-08
申请号：US11421062
申请日：2006-05-30
申请人： Jonathan Zalevsky , Duc-Hanh Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
发明人： Jonathan Zalevsky , Duc-Hanh Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
IPC分类号： C07K14/475 , C07K14/52 , C12P21/06
CPC分类号： C07K14/5759
摘要： An adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin, wherein the adiponectin variant has at least one covalently attached non-peptide moiety at at least one position selected from the group consisting of: A108, Y109, S146, D179, E220, R221, and L224, relative to human adiponectin
摘要翻译： 脂联素变体与人脂联素的残基110-244相比具有至少3倍增加的溶解度，其中所述脂连蛋白变体在选自以下的至少一个位置具有至少一个共价连接的非肽部分：A108， Y109，S146，D179，E220，R221和L224相对于人脂连蛋白
-
公开(公告)号：US20060270598A1
公开(公告)日：2006-11-30
申请号：US11421060
申请日：2006-05-30
申请人： Jonathan Zalevsky , Duc-Hanh Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
发明人： Jonathan Zalevsky , Duc-Hanh Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
IPC分类号： A61K38/17
CPC分类号： A61K38/2264 , A61K31/155 , A61K38/28 , A61K2300/00
摘要： A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin
摘要翻译： 一种用脂联素介导的病症治疗哺乳动物的方法，其包括给予治疗有效量的脂联素变体，其相对于人脂连蛋白的残基110-244具有至少3倍增加的溶解度
-
公开(公告)号：US20150307629A1
公开(公告)日：2015-10-29
申请号：US14673695
申请日：2015-03-30
申请人： Matthew Bernett , Seung Chu , Gregory Moore , John Desjarlais
发明人： Matthew Bernett , Seung Chu , Gregory Moore , John Desjarlais
CPC分类号： C07K16/468 , C07K16/2809 , C07K16/2896 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要： The invention provides novel heterodimeric proteins including heterodimeric antibodies.
摘要翻译： 本发明提供了包括异二聚体抗体的新型异二聚体蛋白。
-
公开(公告)号：US20070010659A1
公开(公告)日：2007-01-11
申请号：US11421059
申请日：2006-05-30
申请人： Jonathan Zalevsky , Duc-Hanh Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
发明人： Jonathan Zalevsky , Duc-Hanh Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
CPC分类号： A61K38/2264
摘要： An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.
摘要翻译： 具有相对于亲本脂联素的一个或多个氨基酸修饰的脂连蛋白变体，其中相对于人脂连蛋白的残基110-244，变体的溶解度提高至少3倍。
-
公开(公告)号：US20060281151A1
公开(公告)日：2006-12-14
申请号：US11421055
申请日：2006-05-30
申请人： Jonathan Zalevsky , Duc-Hanh Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
发明人： Jonathan Zalevsky , Duc-Hanh Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
CPC分类号： C07K14/5759
摘要： An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does not have residues 1-100 relative to human adiponectin, and wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.
摘要翻译： 具有相对于亲本脂联素的一个或多个氨基酸修饰的脂联素变体，其中所述脂联素变体不被糖基化，所述脂联素变体相对于人脂连蛋白不具有1-100的残基，并且其中所述变体的溶解度通过 相对于人脂连蛋白的残基110-244至少3倍。
-
8.发明申请公开(公告)号：US20060276395A1
公开(公告)日：2006-12-07
申请号：US11421061
申请日：2006-05-30
申请人： Jonathan Zalevsky , Duc-Hanh Thi Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
发明人： Jonathan Zalevsky , Duc-Hanh Thi Nguyen , Gregory Moore , Sergei Ezhevsky , John Desjarlais , Arthur Chirino , Darian Cash , Matthew Bernett
IPC分类号： A61K38/17
CPC分类号： A61K38/2264 , A61K47/02
摘要： 1. A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4° C. for one week in 10 mM PO4, 150 mM NaCl buffer.
摘要翻译： 1.包含浓度为至少2.0mg / mL的脂联素变体和药学上可接受的载体的组合物，其中小于20％的所述脂联素变体在4℃下储存一周后在10mM PO中聚集 4mM，150mM NaCl缓冲液。
-
公开(公告)号：US20170037131A1
公开(公告)日：2017-02-09
申请号：US15063441
申请日：2016-03-07
IPC分类号： C07K16/28
CPC分类号： C07K16/2812 , A61K2039/505 , C07K16/2818 , C07K16/2866 , C07K2317/30 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/622
摘要： The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
摘要翻译： 本发明涉及用于调节T细胞的方法和组合物。 调节包括抑制或诱导调节性T细胞或细胞毒性T细胞。
-
公开(公告)号：US20210070824A1
公开(公告)日：2021-03-11
申请号：US16875878
申请日：2020-05-15
申请人： Matthew Bernett , John Desjarlais , Suzanne Schubbert , Christine Bonzon , Rajat Varma , Raphael Clynes
发明人： Matthew Bernett , John Desjarlais , Suzanne Schubbert , Christine Bonzon , Rajat Varma , Raphael Clynes
IPC分类号： C07K14/54
摘要： Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.031 秒)
